ARK fails to get MAA for Cerepro
Today Ark released the negative opinion of EMEA for it's crucial Cerepro- drug.
Today Ark released the negative opinion of EMEA for it's crucial Cerepro- drug.
A strategy that combines gene therapy with blood stem cell therapy may be a useful tool for treating a fatal brain disease, French researchers have found. These findings appear in the 6 November 2009 issue of the journal Science, which is published by AAAS, the nonprofit science society.
Targeted Genetics Corporation (NASDAQ: TGEN) today announced the sale to Genzyme Corporation of certain assets, including manufacturing technologies and other adeno-associated viral (AAV) vector technology, for up to $7 million in cash. The purchased assets consist primarily of patents, know-how and manufacturing-related equipment. Genzyme also received a license to use certain technology and materials necessary for manufacturing AAV vectors.
Roberts Biosolutions Ltd
Hillcoat Place, Edinburgh
United Kingdom
Email: info@genetherapyreview.com
Twitter: @gentherev